1. Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation 
Philippe Armand, Haesook T. Kim, Daniel J. DeAngelo, Vincent T. Ho, Corey S. Cutler, Richard M. Stone, Jerome Ritz, Edwin P. Alyea, Joseph H. Antin, Robert J. Soiffer 
Biology of Blood and Marrow Transplantation 
Volume 13, Issue 6, Pages (June 2007)
DOI: /j.bbmt
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Survival, relapse, and nonrelapse mortality for all de novo patients, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival, (C) cumulative incidence of relapse, (D) nonrelapse mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Overall survival of patients with AML, stratified by cytogenetics according to new grouping scheme. (A) Patients with AML in CR1, (B) patients with AML beyond CR1.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Survival of all patients with therapy-related disease, stratified by cytogenetics according to new grouping scheme. (A) Overall survival, (B) disease-free survival. Note that the favorable group included only 2 patients.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions